Increased incidence of cancer, presence of active product range, cumulative acceptance of sedentary lifestyle leading to rising of metabolic diseases, emerging healthcare markets, are key factors contributing to high CAGR of Peptide Therapeutics market during the forecast period.
Market Size – USD 25.35 Billion in 2018, Market Growth – CAGR of 9.0%, Market Trends– Advancements in Peptide Conjugates, and technological innovations in Peptide Therapeutics.
The global Peptide Therapeutics market was valued at USD 25.35 billion in 2018 and is expected to reach USD 50.60 billion by the year 2026, at a CAGR of 9.0%. Peptide drugs are used as replacement therapies which supplements peptide hormones when the endogenous levels tend to decrease. The first peptide therapeutic was used to treat diabetic patients in the 19th century. The approval for 60 peptides has been granted, with the clinical global administration in the United States, Europe, and Japan. These drugs are used as drug target moiety for cancer, metabolic disorders, cardiovascular disease.
To improve efficiency, conjugates became a boon to alter the properties of proteins. The Polyethylene Glycol (PEG) conjugation, lipids, and proteins have been used for extending the half-life. In recent years, cell-penetrating peptides, termed as ideal transporters, are responsible for assisting the therapeutic cargos in a non-toxic and simple manner being protein, oligonucleotides, nanoparticles. They are currently used in cancer therapy due to its potent and quick delivery.
Furthermore, the report is furnished with the latest impact of the COVID-19 pandemic on the market. The pandemic has affected every segment of the market, along with bringing disruption in the supply chain, demands & trends, and financial difficulties. The report covers the initial and future assessment of the COVID-19 impact on the market.
Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/2770
The report covers the market dynamics analysis, company profiles, production and manufacturing capacity, product specifications, product value, and key players. The report also offers an insight into the growth prospects during the forecast period. The Peptide Therapeutics Market report also offers detailed data on the key market players to impart a deeper understanding of the competitive landscape. The report focuses on the key market elements to ensure the readers gain a competitive advantage and maximum benefit of the market data to assist them in achieving substantial growth and an advantageous position in the global market.
Key findings of the report:
The peptide therapeutics market is expected to reach USD 50.59 billion by the year 2026 at a CAGR of 9.0%, according to the forecast period.
Kallyope, a U.S based company, and Novo Nordisk, a Denmark based Company, entered into a research collaboration and agreement to discover novel therapeutics for treating obesity and diabetes in June 2018.
North America has the largest market share of 38.2% in the year 2018. Its increased dominance in the market is due to the increased investments of Research and Development, high incidence of cancer, and increased demand for healthcare expenditure. The advent of Peptide conjugates will also further drive a rapid increase in the market.
The solid-phase peptide synthesis is expected to reach USD 22.6 billion by the year 2026, showing a good growth market in the year 2026.
Hybrid technology is expected to grow with a CAGR of 8.8% in 2026.
Asia Pacific is hyped to be the largest growing market with a CAGR of 10.2%, with USD 10.51 billion in the forecast period due to high untapped opportunities, affordable cost of raw material, and increasing base of companies providing outsourcing services, flourishing biotech industry, and increasing investments in Research and Development sector. Patent expiration of blockbuster drugs would foster generic market, thus expected to provide significant growth opportunities shortly.
The Cancer type application segment held the largest market share of 37.3% in 2018. Increased occurrence of cancer worldwide and the growing treatment of cancer treatment are the key factors responsible for dominance in this segment.
The Metabolic diseases segment has shown immense market size growth of USD 7.05 billion in 2018 and will show a significant market growth of 8.9% according to the forecast period due to Cumulative acceptance of inactive lifestyle, unhealthy food habits, and consumption of a high amount of alcohol has led to increased occurrence of these disorders.
In May 2018, Bicycle Therapeutics, a biotechnology company showcased a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle) product platform, announced that it is expanding its collaboration with AstraZeneca to include additional targets in respiratory and cardio-metabolic diseases. AstraZeneca is accountable for further development and product commercialization.
PeptiDream, a Japanese biotechnology company, had declared a new peptide drug conjugate (PDC) collaboration with Swiss pharma major Novartis in June 2019. PeptiDream will use its proprietary Discovery Platform System technology to identify unique macrocyclic and constrained peptides, as PDCs against numerous targets of interest, chosen by Novartis.
Computational Biology and screening have good chances of improvement to support drug delivery.
On January 2019, a peptide was received by Leidos Health Life Sciences, for a novel PD-1 checkpoint inhibitor
The Peptide Therapeutics market is fragmented with major players like Sanofi (Australia), Teva Inc (Israel), Novo Nordisk Inc, (Denmark), Takeda (Japan), Eli Lily (United States), Astra Zeneca (U.K.), Novartis (Switzerland), Shire (U.S.) Abbvie (U.S.), Ipsen (France) Allergen (Ireland ), Ferring (Switzerland), Merck (United States), The Medicines (United States), Roche (Switzerland) Johnson and Johnson (United States).
Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/2770
For the purpose of this study, the global Peptide Therapeutics market has been segmented on the basis of disease type, application, distribution channel, and region:
Route of Administration (Revenue in Million USD; 2016–2026)
- Parenteral Route
- Oral Route
Product Type Outlook (Revenue in Million USD; 2016–2026)
Type of Manufacturers (Revenue in Million USD; 2016–2026)
Application Outlook (Revenue in Million USD; 2016–2026)
- Cardiovascular Disorder
Synthesis Outlook (Revenue in Million USD; 2016–2026)
- Solid Phase Peptide Synthesis (SPPS)
- Liquid Phase Peptide Synthesis (LPPS)
- Hybrid Technology
By Region (Revenue, USD Million; 2017-2027)
- Rest of Europe
- South Korea
- Rest of Asia Pacific
- Rest of Latin America
Middle East & Africa
- Saudi Arabia
- Rest of Middle East & Africa
Table Of Contents:
Chapter 1. Market Synopsis
1.1. Market Definition
1.2. Research Scope & Premise
1.4. Market Estimation Technique
Chapter 2. Executive Summary
2.1. Summary Snapshot, 2016 – 2026
Chapter 3. Indicative Metrics
3.1. Macro-Economic Indicators
3.1.1. Increased incidence of cancer, metabolic and cardiovascular diseases.
3.1.2. The need for peptide conjugates.
3.1.3. Increased investment for Research and Development activities in development of drug related to oncology.
Chapter 4. Global Peptide Therapeutics Segmentation & Impact Analysis
4.1. Global Peptide Therapeutics Segmentation Analysis
4.2. Industrial Outlook
4.3. Market Indicators Analysis
4.3.1. Market Drivers Analysis
18.104.22.168. Rise in incidence of chronic diseases.
22.214.171.124. Occurrence of strong products range.
126.96.36.199. Government initiation in drug development related to oncology
4.3.2. Market Restraints Analysis
188.8.131.52. Higher cost of production.
184.108.40.206. The rigid regulations followed.
4.4. Regulatory Framework
4.5. Porter’s Five Forces Analysis
Request customization of the report @ https://www.reportsanddata.com/request-customization-form/2770
Thank you for reading our report. To know more about customization options, please get in touch with us. Our team will ensure the report is tailored to suit your requirements.
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market.
Company Name: Reports and Data
Contact Person: John Watson
Email: Send Email
Address:40 Wall St. 28th floor
City: New York City
State: NY 10005
Country: United States